“This is definitely a positive development for Ranbaxy, Sun and the entire Indian generics Industry. Ranbaxy is a great company and Sun, with its experience and understanding of the generics space, should be able to unlock the true potential and value in Ranbaxy. This unfortunately did not happen under Daiichi Sankyo which failed to harness and assimilate the complexities of running a strong generics business.”
Malvinder Singh
Former shareholder and Ranbaxy founder-family member